SS-31, also known as Elamipretide, should be reviewed as a specification-driven B2B sourcing project. Buyers comparing suppliers should confirm product identity, sourcing format, analytical documentation, quote unit, MOQ, lead time, packaging scope, and destination-market responsibilities before issuing an RFQ or placing a first order.
This guide is written for distributors, private label brand owners, OEM project teams, formulation consultants, and procurement buyers evaluating SS-31 / Elamipretide in bulk powder, lyophilized vial, or custom fill project formats.
It covers sourcing format selection, specification fields, documentation review, MOQ logic, lead time factors, quote basis, supplier qualification checkpoints, and WUMO's project discussion support for qualified B2B inquiries.
This article is not medical advice and does not provide dosing, administration, end-use, therapeutic, disease-related, clinical, or outcome guidance.
SS-31 / Elamipretide: Sourcing Context and Specification Overview
SS-31, also known as Elamipretide, is commonly referenced in peptide sourcing and chemical documentation contexts by the CAS number 736992-21-5. In supplier documentation, it may also appear under related naming conventions such as SS-31 or Elamipretide.
For B2B sourcing review, buyers should treat SS-31 / Elamipretide as a specification-controlled peptide material. The key sourcing question is not only whether a supplier lists the SKU, but whether the supplier can define the material clearly and support the batch with appropriate documentation.
Common identification fields include:
- Peptide name: SS-31 / Elamipretide.
- CAS number: 736992-21-5.
- Molecular formula: C32H49N9O5.
- Molecular weight: approximately 639.8 g/mol, depending on form and supplier documentation.
- Sequence or structural reference: to be confirmed in the supplier specification sheet.
- Appearance: commonly supplied as white to off-white lyophilized powder.
- Common B2B formats: bulk powder and lyophilized vial.
These identification fields should be confirmed against the supplier's specification sheet, COA, HPLC report, and LC-MS or mass confirmation where available. Name matching alone is not enough for supplier qualification.
Sourcing Format Decision: Bulk Powder vs Lyophilized Vial
Bulk powder format
Bulk powder is usually the preferred format when the buyer needs material for downstream processing, specification review, custom fill discussion, or larger-volume sourcing evaluation.
In B2B discussions, bulk SS-31 / Elamipretide may be quoted in milligrams or grams depending on order size and supplier practice. The quotation should state net weight, purity threshold, documentation scope, MOQ, lead time, and shipment assumptions.
Bulk powder may be suitable when:
- The buyer has downstream processing or filling capability.
- The project requires custom fill amounts.
- The buyer wants to separate material cost from vialing and packaging cost.
- The sourcing comparison is being made at peptide-content level.
- A custom lyophilized vial project will be scoped later.
A bulk powder quotation should not be compared directly with a finished vial quotation unless the buyer separates material cost, filling service, packaging, documentation, and shipping scope.
Lyophilized vial format
Lyophilized vial format is relevant when the buyer needs a vial-based project format rather than loose bulk material.
A vial quote should always specify:
- Fill amount per vial.
- Vial size.
- Vial component scope.
- Label scope.
- Vials per box where applicable.
- Documentation package.
- MOQ.
- Lead time.
- Quote unit.
SS-31 / Elamipretide vial fill amounts are not standardized across suppliers. A lower USD/vial quote may reflect a smaller fill amount rather than a better price. Buyers should normalize quotes to peptide content basis, such as USD/mg or USD/g, before comparing suppliers.
For a broader review of vial project scoping, see WUMO's lyophilized peptide vial sourcing guide.
Custom fill and private label discussion
Custom fill means the buyer specifies fill amount, vial format, label scope, and packaging requirements before production. Private label discussion may include buyer-supplied label artwork, outer box design, neutral label options, or project-specific packaging requirements.
Custom fill and private label projects usually require more specification work than catalog vial supply. Buyers should expect a specification alignment step before formal quotation.
Custom fill discussions may include:
- Target fill amount.
- Vial size and component preference.
- Neutral or private label format.
- Box or kit composition.
- MOQ.
- Lead time.
- Documentation package.
- Artwork or label proof requirements.
- Shipment and destination-market considerations.
A private label discussion should not begin with price alone. The buyer should first define the product specification and documentation requirements.
SS-31 / Elamipretide Specification Fields to Review Before Sourcing
Before requesting price, buyers should define the SS-31 / Elamipretide specification fields they want suppliers to quote against.
Important fields include:
- Peptide name and naming consistency.
- CAS number.
- Molecular formula.
- Molecular weight.
- Sequence or structural reference.
- Appearance.
- Purity specification.
- Analytical method.
- Water content where applicable.
- Residual solvent limits where applicable.
- Counterion or salt form where applicable.
- Storage condition.
- Packaging format.
- Shelf-life or retest statement where available.
The specification sheet should be reviewed before the COA whenever possible. The specification sheet defines the expected standard; the COA reports the batch result against that standard.
Because SS-31 / Elamipretide includes non-standard structural features in many supplier references, identity confirmation should be reviewed carefully. Buyers should confirm whether LC-MS or another mass confirmation document is available and whether the observed mass aligns with the theoretical reference used in the specification.
If any field is missing or inconsistent, the buyer should request clarification before comparing the quote with another supplier.
Documentation Package: What to Request for SS-31 / Elamipretide
Certificate of Analysis
A batch-specific COA is the central document for peptide supplier review. For SS-31 / Elamipretide, buyers should confirm that the COA references the specific batch being quoted or shipped.
A useful COA may include:
- Peptide name.
- Batch number.
- Appearance.
- Purity result.
- Test method.
- Molecular weight or identity reference where applicable.
- Water content where applicable.
- Storage condition.
- Analysis date.
- Issuing entity.
A generic COA without batch number has limited traceability value. The COA batch number should match the HPLC report, LC-MS report where available, label, packing list, and physical shipment.
HPLC purity report
An HPLC report supports the purity result shown on the COA. It should ideally include chromatogram, purity figure, peak integration, test date, method information, and batch reference.
Buyers should check:
- Does the HPLC report show the same batch number as the COA?
- Is a chromatogram provided, not only a purity percentage?
- Is the stated purity threshold consistent with the project specification?
- Is the report batch-specific or representative?
- Does the purity figure align with the COA?
A supplier's catalog purity claim should not be treated as equivalent to a batch-specific HPLC result.
LC-MS or mass confirmation
LC-MS or mass spectrometry confirmation helps support molecular identity review. For SS-31 / Elamipretide, mass confirmation can be useful during new supplier qualification or higher-value project review.
A useful mass confirmation document may include:
- Observed mass.
- Theoretical mass.
- Spectrum or method reference.
- Batch or sample reference.
- Test date.
LC-MS may not be included by default for every supplier or every batch. Its absence does not automatically disqualify a supplier, but the buyer should understand whether it can be requested and whether it relates to the supplied batch.
SDS
The Safety Data Sheet supports safety, handling, storage, and transport review. It does not confirm peptide identity or purity.
Buyers should confirm that the SDS:
- Is current.
- Reflects the correct material form.
- Uses a recognizable safety data sheet structure.
- Includes handling and storage information.
- Includes transport information where applicable.
- Can support internal safety and logistics review.
The SDS should be reviewed with the shipment and storage plan, especially for international orders.
Specification sheet
The specification sheet is the quality basis for quotation and supplier comparison. It should define the standard the supplier commits to supply against.
For SS-31 / Elamipretide, a specification sheet may include:
- Product name.
- CAS number.
- Molecular formula.
- Molecular weight.
- Sequence or structural reference.
- Appearance.
- Purity specification.
- Analytical method.
- Water content where applicable.
- Residual solvent limits where applicable.
- Counterion or salt form where applicable.
- Storage condition.
- Packaging format.
- Shelf-life or retest statement where available.
The specification sheet and COA should align. If the COA reports fields that are not defined in the specification sheet, or the specification sheet defines fields not tested in the COA, the buyer should request clarification.
For a broader documentation review method, see WUMO's research-grade peptide shipment documents checklist.
Purity and Peptide Content Considerations
Purity and peptide content are related but not identical. HPLC purity usually reflects the percentage of the main peptide peak under a defined method. Peptide content may be affected by water, counterion, residual solvent, and other material-specific factors.
For B2B sourcing comparison, buyers should clarify:
- What purity threshold is being quoted.
- Which analytical method is used.
- Whether peptide content is reported separately.
- Whether moisture or counterion adjustment is considered.
- Whether the reported result is batch-specific.
- Whether the specification sheet and COA use consistent terminology.
A higher visible purity figure does not automatically make one supplier superior if the method, content basis, and documentation scope are unclear. Buyers should define the required specification before comparing supplier quotes.
MOQ Considerations for SS-31 / Elamipretide
MOQ depends on sourcing format, order size, supplier setup, and project scope.
For bulk powder, MOQ may be discussed in milligrams or grams. For lyophilized vials, MOQ may be based on vial count, batch size, or project setup. For custom fill or private label projects, MOQ may be higher because the supplier must allocate production, filling, packaging, documentation, and coordination resources.
Buyers should clarify:
- Is the MOQ based on grams, vials, boxes, batch size, or order value?
- Is the MOQ for sample, pilot order, or repeat order?
- Is custom fill MOQ different from catalog vial MOQ?
- Are volume tiers available?
- Does the quote include documentation?
- Is packaging included or separate?
- Can the supplier discuss phased ordering?
MOQ should be reviewed together with total peptide content. A smaller vial count with a higher fill amount may require more peptide material than a larger vial count with a lower fill amount.
For broader MOQ and project scale considerations, see WUMO's bulk peptide purchasing guide.
Lead Time Factors for SS-31 / Elamipretide Sourcing Projects
Lead time should be reviewed by project type.
A catalog item in stock may move faster than a made-to-order or custom fill project. A custom vial project may require specification alignment, component availability, production scheduling, QC testing, documentation preparation, and shipment coordination.
Lead time factors may include:
- Peptide material availability.
- Whether synthesis is required.
- Bulk powder packaging.
- Vial filling.
- Lyophilization schedule.
- Label and packaging preparation.
- QC testing.
- Documentation preparation.
- Export documentation.
- Shipment method.
Projects involving non-standard structural features or additional identity confirmation may require more review time than a simple catalog reorder. Buyers should ask whether the quoted timeline reflects the actual project scope.
Buyers should also ask whether the quoted lead time covers only production or also QC, documentation, dispatch, and shipping.
A serious quotation should state lead time assumptions in writing. Chat-based estimates are useful for early discussion, but the formal quotation should define the expected timeline more clearly.
Quote Unit Basis for SS-31 / Elamipretide
SS-31 / Elamipretide quotes may be provided in different unit bases depending on format.
Common quote bases include:
- USD/g for bulk powder.
- USD/mg for smaller evaluation quantities.
- USD/vial for lyophilized vial projects.
- USD/box for kit or multi-vial packaging.
- USD/project for private label or custom fill discussions where setup work is included.
Buyers should not compare these units directly. A USD/vial quote must be reviewed with fill amount. A USD/box quote must be reviewed with vials per box and box contents. A USD/g quote may exclude vialing, packaging, labeling, and shipment scope.
To compare suppliers, buyers should normalize to the same basis, such as USD/mg of SS-31 / Elamipretide content, then separately review packaging, filling, labeling, MOQ, documentation, and lead time.
For full unit comparison logic, see WUMO's guide: Peptide Quote Units Explained: USD/g vs USD/vial vs USD/box.
Storage and Shipment Considerations
Storage and shipment requirements should be confirmed in supplier documentation before dispatch.
For SS-31 / Elamipretide sourcing projects, buyers should review:
- Recommended storage condition.
- Moisture and light sensitivity where applicable.
- Sealed-container guidance.
- Shelf-life or retest statement where available.
- Shipment temperature recommendation.
- Export packaging.
- Packing list.
- Commercial invoice.
- Destination-country import requirements.
Low-temperature storage may be recommended for many peptide materials, but exact requirements should be confirmed from the supplier's specification sheet, label, and shipment documentation.
Cold-chain transit may be discussed for international orders, depending on project requirement, shipment duration, and supplier recommendation. Buyers should confirm shipping method with their logistics partner and supplier before dispatch.
Import classification, permits, labeling obligations, and destination-market compliance remain the buyer's responsibility.
Batch Traceability for SS-31 / Elamipretide
Batch traceability connects the physical material to the supporting document package.
Buyers should confirm that the same batch number appears across:
- COA.
- HPLC report.
- LC-MS report where available.
- Specification or batch reference.
- Label.
- Packing list.
- Physical container.
A supplier that can maintain consistent batch references across documents is easier to evaluate during first-order qualification and repeat ordering.
Batch-specific documentation should be distinguished from representative documentation. A representative COA may be useful for early review, but a formal order should be supported by documents tied to the actual supplied batch where available.
Supplier Qualification Checkpoints for SS-31 / Elamipretide
Supplier qualification should cover both product documentation and project capability.
Key checkpoints include:
- Batch-specific COA is available.
- HPLC report supports the COA purity result.
- LC-MS or mass confirmation is available where requested.
- SDS is current and reflects the supplied form.
- Specification sheet is available before formal order.
- Batch number is consistent across documents.
- Storage condition aligns across label and documentation.
- MOQ is stated by format and unit.
- Lead time is confirmed in writing.
- Quote basis is explicit.
- Fill amount or net weight is stated.
- Custom fill or private label scope is clearly defined.
- Communication quality is sufficient for B2B project coordination.
For a broader supplier review method, see WUMO's peptide supplier qualification checklist.
How WUMO Supports Qualified SS-31 / Elamipretide B2B Project Discussion
WUMO supports qualified B2B buyers with SS-31 / Elamipretide sourcing discussion, specification review, documentation review, and project quotation support.
For SS-31 / Elamipretide projects, WUMO can help buyers clarify:
- Bulk powder or lyophilized vial format.
- Documentation scope.
- COA, HPLC, LC-MS, SDS, and specification sheet availability.
- MOQ and volume tier discussion.
- Lead time assumptions.
- Quote basis.
- Custom fill feasibility.
- Neutral label or private label discussion.
- Packaging scope.
- Project fit before formal quotation.
Availability may vary by batch, project type, destination requirement, and buyer specification. Buyers are encouraged to state format, documentation, MOQ, and packaging requirements before quotation so the project can be reviewed properly.
Frequently Asked Questions
What is the CAS number for SS-31 / Elamipretide?
SS-31 / Elamipretide is commonly referenced in sourcing documentation by CAS number 736992-21-5. Buyers should verify CAS number, molecular formula, molecular weight, and batch documentation against the supplier's specification sheet and COA.
What documentation should B2B buyers request when sourcing SS-31 / Elamipretide?
Common documents may include batch-specific COA, HPLC report, LC-MS or mass confirmation where available, SDS, specification sheet, packing list, commercial invoice, storage statement, and batch number reference.
What is a typical purity specification for research-grade SS-31 / Elamipretide?
Purity specification depends on project requirements and supplier capability. Buyers should define the required threshold in the specification sheet and confirm that COA and HPLC results support the same standard.
What is the molecular weight of SS-31 / Elamipretide?
SS-31 / Elamipretide is commonly referenced with a molecular weight of approximately 639.8 g/mol, depending on form and supplier documentation. Buyers should confirm the theoretical and observed mass in supplier documents where available.
What is the difference between bulk powder and lyophilized vial format for SS-31 / Elamipretide sourcing?
Bulk powder is generally used for downstream processing, formulation, or custom fill discussion. Lyophilized vial format is used when the buyer needs a defined vial-based project format. The two formats should not be compared without normalizing quote unit and project scope.
What do non-standard structural features mean for SS-31 / Elamipretide sourcing?
They mean buyers should review identity documentation more carefully. Specification sheet, LC-MS or mass confirmation where available, and batch-linked analytical records can help support supplier qualification.
How should buyers compare SS-31 / Elamipretide quotes across suppliers?
Buyers should normalize quotes to the same peptide-content basis, such as USD/mg or USD/g. They should then compare documentation, MOQ, lead time, packaging scope, vial fill amount, and shipment terms separately.
What storage conditions are standard for SS-31 / Elamipretide lyophilized peptide?
Storage conditions should be confirmed from the supplier's specification sheet, label, and shipment documentation. Many peptide materials may require low-temperature storage, moisture control, or protection from light, but exact conditions should be batch and supplier specific.
What MOQ and lead time should B2B buyers expect for SS-31 / Elamipretide?
MOQ and lead time vary by supplier, product form, fill amount, packaging scope, and whether the item is in stock or made to order. Buyers should request volume tiers and a lead time breakdown before comparing suppliers.
What is the difference between HPLC purity and peptide content for SS-31 / Elamipretide?
HPLC purity usually reflects the main peak percentage under a defined method. Peptide content may account for water, counterion, residual solvent, or other material-specific factors. Buyers should clarify which metric is being quoted.
Is endotoxin testing standard for SS-31 / Elamipretide vial format?
Endotoxin testing is not automatically standard for every supplier or project. If it is required for a buyer's downstream review, it should be requested explicitly at the RFQ stage and confirmed in the documentation scope.
How does counterion form affect SS-31 / Elamipretide specification review?
Counterion or salt form may affect net peptide content, molecular weight reference, and documentation comparison. Buyers should confirm the stated form in the specification sheet and COA before comparing suppliers.
What shipment documents are typically required for SS-31 / Elamipretide cross-border sourcing?
Common shipment documents may include commercial invoice, packing list, SDS, COA, and storage or handling statement. Requirements vary by destination market, shipment route, and customs broker guidance.
Can WUMO support custom fill or private label projects involving SS-31 / Elamipretide?
WUMO can discuss custom fill, neutral label, and private label project requirements with qualified B2B buyers. Feasibility depends on project scope, MOQ, documentation requirements, destination considerations, and supplier-side review.
CTA
Qualified B2B buyers sourcing SS-31 / Elamipretide for research-grade projects are welcome to submit a project inquiry.
WUMO supports bulk powder, lyophilized vial, and custom fill discussions with documentation review for qualified B2B projects.